HER2-positive breast cancers represent a significant breast cancer subtype, while recent research has revealed that certain heterogeneities also exist within this entity, and distinct HR statuses may contribute mainly to different treatment responses, metastatic patterns, and survival outcomes (35, 36). Here, ERBB2 is linked to breast carcinoma.